Skip to Main Content

Paper Details

Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
Vasc Med
16
2020
CAD, MACE, MALE, MI, PAD, TRA, Vorapaxar, coronary artery disease, ischemic stroke, patients, peripheral artery disease, vorapaxar
Author NameAffiliation
David A MorrowBrigham and Women's Hospital and Harvard Medical School
David A MorrowBrigham and Women's Hospital and Harvard Medical School
Mark A CreagerGeisel School of Medicine at Dartmouth
Mark A CreagerGeisel School of Medicine at Dartmouth
Benjamin M SciricaBrigham and Women's Hospital and Harvard Medical School
Jeffrey W OlinZena and Michael A Weiner Cardiovascular Institute and Marie-Jose and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai
Joshua A BeckmanVanderbilt Heart and Vascular Institute
  • 1 - 7

Datasets